Henry Wang

Background/Objectives: Ureteric stents are commonly used in the management of urolithiasis but are associated with significant morbidity, leading to unplanned emergency department presentations and increased healthcare utilisation. This study aimed to evaluate whether reducing ureteric stent dwell time from three months to one month was associated with reduced stent-related emergency presentations. Secondary objectives were to assess post-ureteroscopy infective complications and identify predictors of emergency attendance. Methods: A retrospective cohort study was conducted across Western Sydney Local Health District, comparing patients undergoing ureteric stenting prior to ureteroscopy before (n = 189) and after (n = 244) an institutional policy change reducing time to definitive surgery from three months to one month. Patients aged ≥16 years with urolithiasis were included. Results: Following the policy change, mean waiting time for ureteroscopy decreased from 97.3 to 40.6 days. The proportion of patients presenting to the emergency department (ED) for stent-related symptoms decreased from 31.7% to 16.4% (p < 0.001), and mean presentations per patient declined from 0.60 to 0.21 (p < 0.001). Stent irritation accounted for most presentations. Using multivariable analysis, age < 50 years, immunosuppression, and positive pre-operative urine cultures were independently associated with ED attendance. Post-ureteroscopy infective complications were lower in the shortened dwell-time cohort (2.0% vs. 4.2%) but did not reach statistical significance (p = 0.26). Conclusions: Reducing routine ureteric stent dwell time from three months to one month was associated with significantly fewer stent-related emergency presentations. Shorter dwell protocols may reduce patient morbidity and healthcare utilisation and could be associated with lower rates of post-ureteroscopy infective complications.

There is not a clear consensus on which pathological features and biomarkers are important in guiding prognosis and adjuvant therapy in colon cancer. The Pathology in Colon Cancer, Prognosis and Uptake of Adjuvant Therapy (PiCC UP) Australia and New Zealand questionnaire was distributed to colorectal surgeons, medical oncologists and pathologists after institutional board approval. The aim of this study was to understand current specialist attitudes towards pathological features in the prognostication of colon cancer and adjuvant therapy in stage II disease. A 5-scale Likert score was used to assess attitudes towards 23 pathological features for prognosis and 18 features for adjuvant therapy. Data were analysed using a rating scale and graded response model in item response theory (IRT) on STATA (Stata MP, version 15; StataCorp LP). One hundred and sixty-four specialists (45 oncologists, 86 surgeons and 33 pathologists) participated. Based on IRT modelling, the most important pathological features for prognosis in colon cancer were distant metastases, lymph node metastases and liver metastases. Other features seen as important were tumour rupture, involved margin, radial margin, CRM, lymphovascular invasion and grade of differentiation. Size of tumour, location, lymph node ratio and EGFR status were considered less important. The most important features in decision making for adjuvant therapy in stage II colon cancer were tumour rupture, lymphovascular invasion and microsatellite instability. BRAF status, size of tumour, location, tumour budding and tumour infiltrating lymphocytes were factored as lesser importance. Biomarkers such as CDX2, EGFR, KRAS and BRAF status present areas for further research to improve precision oncology. This study provides the most current status on the importance of pathological features in prognostication and recommendations for adjuvant therapy in Australia and New Zealand. Results of this nationwide study may be useful to help in guiding prognosis and adjuvant treatment in colon cancer.

The prognostication of colorectal cancer (CRC) has traditionally relied on staging as defined by the Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) TNM staging classifications. However, clinically, there appears to be differences in survival patterns independent of stage, suggesting a complex interaction of stage, pathological features, and biomarkers playing a role in guiding prognosis, risk stratification, and guiding neoadjuvant and adjuvant therapies. Histological features such as tumour budding, perineural invasion, apical lymph node involvement, lymph node yield, lymph node ratio, and molecular features such as MSI, KRAS, BRAF, and CDX2 may assist in prognostication and optimising adjuvant treatment. This study provides a comprehensive review of the pathological features and biomarkers that are important in the prognostication and treatment of CRC. We review the importance of pathological features and biomarkers that may be important in colorectal cancer based on the current evidence in the literature.